http://rdf.ncbi.nlm.nih.gov/pubchem/reference/27588557

Outgoing Links

Predicate Object
contentType Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't
endingPage 14
issn 1558-7673
issueIdentifier 1
pageRange 6-14
publicationName Clinical Genitourinary Cancer
startingPage 6
bibliographicCitation Fleming MT, Sonpavde G, Kolodziej M, Awasthi S, Hutson TE, Martincic D, Rastogi A, Rousey SR, Weinstein RE, Galsky MD, Berry WR, Wang Y, Boehm KA, Asmar L, Rauch MA, Beer TM. Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2012 Mar;10(1):6–14. doi: 10.1016/j.clgc.2011.11.003. PMID: 22340631.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cb7b7d10d298acf2d0125fd8db3dfff6
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c783d8f0b425fdc80c5f5b641bf7ea8f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6cc8e4fd4a9d5e916d3bc8901f09d51c
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e505957caefb57a1023955cbe2a9d63d
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ef8a89d5e20b8f03ecf056ce025b43a7
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f7044ca93fcf7403d2bd1f4cbc3eb50a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_88f3ae0b62606c948fb7857585dd37a7
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f60405cdd8a95970c483df450ec7bfc1
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8b0718eebcf23833b8d6d6b2c21b1a80
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_04caeff921dc084e6cfc512bc820e74e
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1de4f882c005cdb54014dce945265d5f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b15fe211e7cbad0d52db839cfdc2370a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ff49747aa2a6e6927e5426ffa50fbbcd
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_47dc7dbab1a0d0ca0984a7ed0c486fad
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-5214-5717
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_20334672392b7db731410a3562f89d66
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_92c085725fb1af86f3848eb796f45c63
date 201203
identifier https://pubmed.ncbi.nlm.nih.gov/22340631
https://doi.org/10.1016/j.clgc.2011.11.003
isPartOf https://portal.issn.org/resource/ISSN/1558-7673
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/32764
language English
source https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title Association of Rash With Outcomes in a Randomized Phase II Trial Evaluating Cetuximab in Combination With Mitoxantrone Plus Prednisone After Docetaxel for Metastatic Castration-resistant Prostate Cancer
discusses http://id.nlm.nih.gov/mesh/M0422675
http://id.nlm.nih.gov/mesh/M0017465
http://id.nlm.nih.gov/mesh/M0001357
http://id.nlm.nih.gov/mesh/M0443608
http://id.nlm.nih.gov/mesh/M0556300
http://id.nlm.nih.gov/mesh/M0013954
http://id.nlm.nih.gov/mesh/M0184558
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D009919
http://id.nlm.nih.gov/mesh/D005076Q000139
http://id.nlm.nih.gov/mesh/D000230Q000188
http://id.nlm.nih.gov/mesh/D000971Q000009
http://id.nlm.nih.gov/mesh/D011471Q000188
hasSubjectTerm http://id.nlm.nih.gov/mesh/D005076Q000188
http://id.nlm.nih.gov/mesh/D000230Q000556
http://id.nlm.nih.gov/mesh/D043823Q000008
http://id.nlm.nih.gov/mesh/D000230Q000401
http://id.nlm.nih.gov/mesh/D008875
http://id.nlm.nih.gov/mesh/D008942Q000008
http://id.nlm.nih.gov/mesh/D015996
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D011241Q000008
http://id.nlm.nih.gov/mesh/D000068818
http://id.nlm.nih.gov/mesh/D016896
http://id.nlm.nih.gov/mesh/D061067
http://id.nlm.nih.gov/mesh/D008297
http://id.nlm.nih.gov/mesh/D000911Q000008
http://id.nlm.nih.gov/mesh/D005500
http://id.nlm.nih.gov/mesh/D000077143
http://id.nlm.nih.gov/mesh/D000369
http://id.nlm.nih.gov/mesh/D000368
http://id.nlm.nih.gov/mesh/D011471Q000473
http://id.nlm.nih.gov/mesh/D011471Q000401
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9408
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8983
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8661
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID148124
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6873
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4212
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5995
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_fce276cc0efd2412c7dafdbb1e82fcc8
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7660
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5865
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_fddb60309b0ee16f8cd57b4b90c99e89
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_3.4.21.77
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7706

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129717275
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128397534
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129159660

Total number of triples: 84.